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Statement of findings
Protein truncation test (PTT) and single-strand conformation polymorphism (SSCP) assay
were used to scan the BRCA1 and BRCA2 genes in 136 unrelated Italian breast/ovarian
cancer patients. In the sample tested, BRCA1 and BRCA2 equally contributed to site-
specific breast cancer patients who reported one to two breast cancer-affected first-/
second-degree relative(s) or who were diagnosed before age 40 years in the absence of a
family history of breast/ovarian cancer. BRCA1 and BRCA2 mutations were mostly found in
patients with disease diagnosis before and after age 50 years, respectively. Moreover, in
cases with familial clustering of site-specific breast cancer, BRCA1 mostly accounted for
tumours diagnosed before age 40 years and BRCA2 for tumours diagnosed after age 50
years. The BRCA1 and BRCA2 mutation spectrum was consistent with a lack of significant
founder effects in the sample of patients studied.
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CASH = Contraceptive and Steroid Hormones; PCR = polymerase chain reaction; PTT = protein truncation test; SSCP = single-strand conforma-
tion polymorphism.
Introduction: Germline BRCA1 and  BRCA2 mutations
account for most hereditary breast/ovarian cancers and are
associated with male breast cancer. Furthermore, constitutional
mutations in these genes may occur in breast/ovarian cancer
patients that do not meet stringent criteria of autosomal-
dominant predisposition. The relevance of BRCA1 and
BRCA2 mutations in such patients is still debated.
Objectives: We sought to determine the impact of BRCA1
and BRCA2 mutations in a population of patients from central
and southern Italy. We analyzed the BRCA1 and BRCA2
coding regions in 136 unrelated probands: 117 females with
breast/ovarian cancer and 19 males with breast cancer. This
population of patients was mostly representative of cases who
are at risk for hereditary susceptibility, but who do not meet
stringent criteria of autosomal-dominant predisposition.
Methods: Probands, subclassified as follows, were
consecutively recruited depending on informed consent from
patients attending breast cancer clinics in Rome and Naples.
Selection criteria for females were as follows: breast cancer
with breast cancer family history [one to two first-/second-
degree relative(s), n = 55]; breast cancer diagnosed before
age 40 years (no breast/ovarian cancer family history, n = 28);
bilateral breast cancer (regardless of age and family history,
n = 10); breast cancer associated with gastrointestinal,
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pancreatic or uterine cancers [synchronous/metachronous or
in first-degree relative(s), n = 9]; breast or ovarian cancer with
family history of breast–ovarian/ovarian cancer (at least 1 first-/
second-degree relative, n = 10); and ovarian cancer with no
breast/ovarian cancer family history (n = 5). Males with breast
cancer were recruited regardless of age and family history.
BRCA1 exon 11 and BRCA2 exons 10 and 11 were screened
by PTT. Coding BRCA1 exons 2, 3, 5–10 and 12–24 and
BRCA2 exons 2–9 and 12–27 were screened by SSCP.
Primers are listed in Table 1. In 27 cases, analyzed by PTT
along the entire BRCA1 coding sequence, BRCA1 SSCP
analysis was limited to exons 2, 5, 20 and 24. Mutations were
verified by sequence analysis on two independent blood
samples.
Results: Deleterious germline BRCA1/BRCA2 mutations were
detected in 11 out of 136 cases (8%). Only three BRCA2
mutations were novel. One BRCA2 mutation recurred in two
unrelated probands. Table 2 shows the mutations and data
concerning carriers and their families. Table 3 shows
correlations between BRCA1/BRCA2 mutations and sex, age
at disease diagnosis and familial clustering of breast/ovarian
cancer in the total patient population. Table 4 shows the
proportions of BRCA1 and BRCA2 mutations in females with
site-specific breast and breast–ovarian/ovarian cancer. Table 5
shows the frequency of BRCA1/BRCA2 mutations in males.
BRCA1 and  BRCA2 mutations, respectively, accounted for
four out of 68 (6%) and one out of 68 (1%) cases diagnosed
before age 50 years, and for one out of 68 (1%) and five out of
68 (7%) cases diagnosed after age 50 years. BRCA1
mutations were found in five out of 117 females (4%) and in
none of 19 males (0%), and BRCA2 mutations were found in
four out of 117 females (3%) and in two out of 19 males
(10%). The proportions of BRCA1 and BRCA2 mutations
coincided in site-specific female breast cancers (four out of
102; ie 4% each). BRCA1 and BRCA2 equally contributed to
female breast cancers, with no familial clustering in those
diagnosed before age 40 years (one out of 28; 4% each), and
to female breast cancers, all ages, with familial clustering in one
to two relatives (three out of 55; ie 5% each). In the latter
subset of cases, BRCA1 mostly accounted for tumours
diagnosed before age 40 years (two out of eight; 25%), and
BRCA2 for tumours diagnosed after age 50 years (three out of
34; 9%). Regardless of family history, the respective
contributions of BRCA1 and BRCA2 to site-specific female
breast cancers diagnosed before age 40 years were 8% (three
out of 36) and 3% (one out of 36). One BRCA1 mutation was
detected among the 15 female probands from
breast–ovarian/ovarian cancer families (7%). Among male
breast cancers, BRCA2 mutations were identified in one out of
five (20%) cases with family history and in one out of 14 (7%)
apparently sporadic cases. No BRCA1 or BRCA2 mutations
were found in female probands with nonfamilial bilateral breast
cancer (10 cases) or in those with breast cancer associated
with gastrointestinal, pancreatic or uterine cancers,
synchronous/metachronous or in first-degree relative(s) (nine
cases). These cases were all diagnosed after age 40 years.
Discussion: Our results indicate a lack of relevant founder
effects for BRCA1- and BRCA2-related disease in the sample
of patients studied, which is consistent with other Italian
studies and with ethnical and historical data. Overall, the
Table 1
Oligonucleotide primers used for PTT and SSCP analyses
Exon screened Primer
PTT
BRCA1 exon 11 Br5¢-S: 5¢-GCTGCTTGTGAATTTTCTGAG-3¢
Br5¢-A: 5¢-GCCTGCAGTGATATTAACTGTCTG-3¢
Br3¢-S: 5¢-GAAGAAAGTGAACTTGATG-3¢
Br3¢-A: 5¢-TAAGTTTGAATCCATGCTTTG-3¢
BRCA2 exon 10 B10-S: 5¢-TTTGGAAAAACATCAGGGAATT-3¢
B10-A: 5¢-AAACACAGAAGGAATCGTCATC-3¢
BRCA2 exon 11 B11-1S: 5¢-CATTCTTCTGTGAAAAGAAGCTG-3¢
B11-1A: 5¢-TGGTTTGAATTAAAATCCTGC-3¢
B11-2S: 5¢-TACATGAACAAATGGGCAGGAC-3¢
B11-2A: 5¢-TCCAGTACCAACTGGGACAC-3¢
B11-3S: 5¢-GATCAGAAACCAGAAGAATTGC-3¢
B11-3A: 5¢-TTGGGATATTAAATGTTCTGGAGTA-3¢
B11-4S: 5¢-TCACCTTGTGATGTTAGTTTG-3¢
B11-4A: 5¢-GTTAGCATACCAAGTCTACTG-3¢
SSCP
BRCA1 exons 2, 3, 5–10, 12–24 Reported by Friedman et al [17]
BRCA2 exons 2–9, 12, 13, 15, 16, 19–27 Reported by Friedman et al [11]
BRCA2 exon 14 B14-S: 5¢-GTGTACTAGTCAATAAAC-3¢
B14-A: 5¢-CATCACACAAATTGTCAT-3¢
BRCA2 exon 18 B18-S: 5¢-GAATTCTAGAGTCACACTTCCT-3¢
B18-A: 5¢-ACTGATTTTTACCAAGAGTGCA-3¢
Sense primers used for PTT contain a T7 promoter and a eukaryotic translation initiation sequence: 5¢-GGATCCTAATACGACTCACTATAGGGA-
GACCACCATG-3¢. A, antisense; S, sense.http://breast-cancer-research.com/content/2/4/307
Table 2
Germline BRCA1 and BRCA2 mutations detected in selected samples from 136 unrelated probands and clinicopathologic correlations
Sex Type of cancer Family history Gene Exon Codon Nucleotide Effect
Female Br (26) None BRCA1 11 454 1479 delAG-ter454
Female Ov (45)  Mo: Ov (57) BRCA1 11 502 1623 5bpdel-ter505
Female Br (64) D: Br (24) BRCA1 11 1254 3880 delAG-ter1265
D: Br (41)
Female Br (38) Fa: Ga (64) BRCA1 5 61 300 Cys/Gly
Pa: Br (50)
Female bil Br (40) Mo: Br (49) BRCA1 16 1655 5083 del19bp-ter1670
Male Br (79) S: Br (35) BRCA2 11 1293 4109 TTA-TAA 
S: Br (55) (Lys-Stop)
S: Br (50)
S: Col (47)
Female Br (55) S: Br (49) BRCA2 11 1370 4339 CAG-TAG
S: Pan (52) (Glu-Stop)
B: Col (54)
Female Br (62) Mo: Br (59) BRCA2 11 1629 5117 TCA-TGA
(Ser-Stop)
Male Br (54) None BRCA2 11 1906 5950 delCT-ter1909
Female Br (57) S: Br (50) BRCA2 11 2156 6696 delTC-ter2174
2Female Br (34) None BRCA2 11 2156 6696 delTC-ter2174
Numbers in parentheses indicate age at onset. B, brother; bil Br, bilateral breast cancer; Br, breast cancer; Col, colorectal cancer; D, daughter; Fa,
father; Ga, gastric cancer; Mo, mother; Ov, ovarian cancer; Pa, paternal aunt; Pan, pancreatic cancer; S, sister.
Table 3
BRCA1 and BRCA2 mutations by sex, age at disease diagnosis and presence of breast/ovarian cancer in first-/second-degree
relative(s) in the total population of 136 breast/ovarian cancer probands analyzed
BRCA1 BRCA2 Total
Characteristics of patients Positive (%) Negative Positive (%) Negative Positive (%) Negative
Age
50 years or under 4 (6) 64 1 (1) 67 5 (7) 63
Older than 50 years 1 (1) 67 5 (7) 63 6 (9) 62
Sex
Female 5 (4) 112 4 (3) 113 9 (8) 108
Male 0 (0) 19 2 (10) 17 2 (10) 17
Cancer in relative(s)
Yes 4 (6) 66 4 (6) 66 8 (11) 62
No 1 (1) 65 2 (3) 64 3 (4) 63
Positive indicates the presence of deleterious mutations, whereas negative indicates the absence of such mutations.
contribution of BRCA1 and BRCA2 to breast/ovarian cancer in
Italian patients appears to be less significant than in patients
from communities with founder mutations. The present study is
in agreement with direct estimates on other outbred
populations, indicating that 7–10% of all female breast cancers
that occur in patients aged under 40 years are due to
BRCA1/BRCA2.
We found that BRCA1 and BRCA2 equally contributed to site-
specific breast cancers who had one/two breast cancer-
affected first-/second-degree relative(s) or who were
diagnosed within age 40 years in the absence of family history.
This is consistent with recent data that indicated that the
respective frequencies of BRCA1 and BRCA2 mutations are
comparable in early onset breast cancer. Considering the total
population of patients analyzed here, however, BRCA1 and
BRCA2 mutations were mostly found in cases with disease
diagnosis before and after age 50 years, respectively.
Moreover, in cases with familial clustering of site-specificBreast Cancer Research    Vol 2 No 4 Ottini et al
Table 4
Proportions of BRCA1 and BRCA2 mutations in 117 female breast/ovarian cancer probands, classified by number of cancer
patients in the family, age at disease diagnosis, site-specific breast or breast–ovarian/ovarian cancer
Age of proband at disease diagnosis
40 years or less 41–50 years 51 years or more All ages
Cancer patients BRCA1 BRCA2 BRCA1 BRCA2 BRCA1 BRCA2 BRCA1 BRCA2
in family† [% (n)] [% (n)] [% (n)] [% (n)] [% (n)] [% (n)] [% (n)] [% (n)]
Breast
One 4 (1/28) 4 (1/28) 0 (0/9)* 0 (0/9)* 0 (0/10)* 0 (0/10)* 2 (1/47)* 2 (1/47)*
Two or three 25 (2/8) 0 (0/8) 0 (0/13) 0 (0/13) 3 (1/34) 9 (3/34) 5 (3/55) 5 (3/55)
Total 8 (3/36) 3 (1/36) 0 (0/22) 0 (0/22) 2 (1/44) 7 (3/44) 4 (4/102) 4 (4/102)
Breast/ovary
None/one 0 (0/1) 0 (0/1) 0 (0/1) 0 (0/1) 0 (0/3) 0 (0/3) 0 (0/5) 0 (0/5)
None to two/ – – 25 (1/4) 0 (0/4) 0 (0/6) 0 (0/6) 10 (1/10) 0 (0/10)
one or two
Total 0 (0/1) 0 (0/1) 20 (1/5) 0 (0/5) 0 (0/9) 0 (0/9) 7 (1/15) 0 (0/15)
†Including proband; numbers of BRCA1- and BRCA2-positive cases over number of cases in each age subset are given in parentheses. *The 19
breast cancer patients with no familial clustering of breast/ovarian cancer diagnosed above age 40 years included 10 cases with bilateral breast
cancer and nine patients with breast cancer associated with gastrointestinal, pancreatic or endometrial cancer (synchronous/metachronous, four
cases; in a first-degree relative, five cases).
Table 5
Proportions ofBRCA1 and BRCA2 mutations in 19 male breast cancer probands classified by number of cancer patients in the
family and age at disease diagnosis
Age of proband at disease diagnosis
41–50 years 51 years or more All ages
Cancer patients BRCA1 BRCA2 BRCA1 BRCA2 BRCA1 BRCA2
in family* [% (n)] [% (n)] [% (n)] [% (n)] [% (n)] [% (n)]
One 0 (0/1) 0 (0/1) 0 (0/13) 8 (1/13) 0 (0/14) 7 (1/14)
Two or three 0 (0/3) 0 (0/3) 0 (0/2) 50 (1/2) 0 (0/5) 20 (1/5)
Total 0 (0/4) 0 (0/4) 0 (0/15) 13 (2/15) 0 (0/19) 10 (2/19)
*Including proband; numbers of BRCA1- and BRCA2-positive cases over number of cases in each age subset are given in brackets. 
breast cancer, BRCA1 mostly accounted for tumours
diagnosed before age 40 years, and BRCA2 for tumours
diagnosed after age 50 years. This is in agreement with a
trend, which has been observed in other populations, for the
proportion of cases with BRCA2 mutations to increase, and
the proportion with mutations in BRCA1 to decrease, as the
age at cancer onset increases.
As in other studies, the frequency of BRCA1/BRCA2
mutations taken together was lower than the estimated
frequencies at comparable ages for all susceptibility alleles
derived from the Contraceptive and Steroid Hormones (CASH)
study. The discrepancy between direct data deriving from
BRCA1/BRCA2 mutational analysis and CASH estimates
could be due to several factors, including contribution of
gene(s) other than BRCA1/BRCA2, differences between
populations and relative insensitivity of mutational screening.
Only BRCA1 mutations were found in breast/ovarian and site-
specific ovarian cancer families. BRCA2, but not BRCA1
mutations were found in the male breast cancers. The overall
proportion of males with BRCA2 mutations was high when
compared with data from other studies on outbred populations,
but was low compared with data from populations with founder
effects.
The present results should be regarded as an approximation,
because the following types of mutation are predicted to
escape detection by the screening strategy used: mutations in
noncoding regions; missense mutations within BRCA1 exon
11 and BRCA2 exons 10 and 11; large gene deletions; and
mutations within the first and last 180 nucleotides of the
amplicons analyzed by PTT.Introduction
The proportion of breast cancers that are attributable to
autosomal-dominant susceptibility genes is estimated to
be approximately 7% in the general population [1–4].
Germline mutations of the BRCA1 and BRCA2 genes are
estimated to contribute to the majority of the breast
cancers that have very early disease onset, strong family
history and/or association with ovarian cancer [4–6].
BRCA1 and BRCA2 also account for a proportion of
common breast/ovarian cancer patients that typically do
not meet stringent criteria for highly penetrant autosomal-
dominant cancer predisposition, but rather report one or
two disease-affected relatives and/or manifest an early
disease onset [4,6,7]. Knowledge of the contribution of
BRCA1 and BRCA2 to breast cancer in these patients is
still incomplete [4–8]. A better understanding of the fre-
quencies of BRCA1 and BRCA2 mutations in such mod-
erate risk patients is fundamental to our appreciation of
the importance of these genes as a cause of disease in
the general population. Furthermore, BRCA2 and, to a
lesser extent, BRCA1 also appear to be responsible for an
important, but still debated proportion of male breast
cancers [4,9–14].
We analyzed the entire BRCA1 and BRCA2 coding
regions in 136 unrelated probands: 117 female breast/
ovarian cancer patients and 19 male breast cancer
patients. This sample, selected from patients attending
breast cancer clinics in Rome and Naples, was primarily
drawn from moderate-risk families originating from central
and southern Italy, a geographic region that is known to be
ethnically heterogeneous [15]. We used a screening strat-
egy based on a combination of PTT and SSCP analyses,
techniques that are mutually complementary in sensitivity
and that may identify more than 80% of mutations [16].
Patients and methods
Patients
A total of 136 probands, subclassified as listed below
according to selection criteria, were consecutively
recruited depending on informed consent from among
breast/ovarian cancer patients attending the breast cancer
clinics participating in the study in Rome and Naples. The
patients originated from the regions of Latium and Abruzzo
(central Italy) and Campania and Molise (southern Italy).
They included 55 patients with female breast cancer, any
age, with breast cancer in one or two first-/second-degree
relative(s); 28 patients with female breast cancer diag-
nosed before age 40 years, who reported no family history
of breast/ovarian cancer; 10 patients with female
breast/ovarian cancer, any age, with a family history of
ovarian/breast–ovarian cancer in at least one first-
/second-degree relative; 19 patients with male breast
cancer, selected regardless of age and family history; five
patients with ovarian cancer, any age, who reported no
familial history of breast/ovarian cancer; 10 patients with
bilateral breast cancer, selected regardless of age, who
reported no family history of breast/ovarian cancer; and
nine patients with breast cancer associated with gastroin-
testinal, pancreatic or uterine cancers, synchronous/meta-
chronous, or in first-degree relative(s), selected regardless
of age. Analysis of genomic DNA, RNA and cDNA prepa-
rations from peripheral blood lymphocytes were performed
following standard procedures. The research protocol was
approved by the ethical committee of the University
‘Gabriele D’Annunzio’.
BRCA1 and BRCA2 mutational analysis
All patients were analyzed for constitutional mutations
throughout the entire BRCA1 and BRCA2 coding
regions.  BRCA1 exon 11 and BRCA2 exons 10 and 11
were screened by PTT from genomic DNA using the
primers listed in Table 1. Coding BRCA1 exons 2, 3,
5–10 and 12–24, and BRCA2 exons 2–9 and 12–27
were screened by SSCP analysis using previously
reported primers [11,17]. Primers for BRCA2 exons 14
and 18 and for a 281 bp BRCA2 fragment that encom-
passed the intron 10/exon 11 boundary are reported in
Table 1. In 27 cases, who were analyzed by PTT along the
entire BRCA1 coding sequence as described by Fried-
man et al [17], BRCA1 SSCP analysis was limited to
exons 2, 5, 20 and 24, to identify missense mutations that
are reportedly frequent in these exons and to allow a
better investigation of the 5¢ and 3¢ ends of the coding
sequence. PTT and polymerase chain reaction
(PCR)-SSCP were performed as described previously
[11,17,18]. When truncated peptides or variant SSCP
conformers were identified, genomic DNA was reamplified
and directly sequenced with the PCR product sequencing
kit (Sequenase Version 2.0, USB-Amersham, Cleveland,
OH, USA). Mutations were verified on two independent
blood samples.
Results
Deleterious germline BRCA1/BRCA2 mutations were
detected in 11 out of 136 cases (8%). Table 2 shows the
mutations and data concerning carriers and their families.
Table 3 shows correlations between BRCA1/BRCA2
mutations and sex, age at disease diagnosis and familial
clustering of breast/ovarian cancer in the total patient pop-
ulation. Table 4 shows the proportions of BRCA1 and
BRCA2 mutations in females with site-specific breast and
breast–ovarian/ovarian cancer. Table 5 shows the fre-
quency of BRCA1/BRCA2 mutations in males.
The five deleterious BRCA1 mutations (Table 2) included
four frameshift mutations (BRCA1 1479delAG, BRCA1
1623del5bp,  BRCA1  3880delAG,  BRCA1  5083del19bp)
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Full articleand one missense mutation (BRCA1 300TtoG). These
mutations were already reported in the literature [18–22]
or in the Breast Cancer Information Core electronic data-
base (http://nchgr.nih.gov/Intramural_research/Lab_trans-
fer/Bic/). In addition to the above described deleterious
mutations, the neutral BRCA1 coding variants
Glu1038Gly and, in homozygosity, Ser1613Gly were
found in two patients [20]. A novel C to G transversion,
affecting the conserved C/T residues of the consensus
sequence for the 3¢-splice site of BRCA1 intron 22, was
also found in a 60-year-old woman with synchronous
breast and gastric cancers, but no family history of cancer.
Sequence analysis from cDNA and genomic DNA
revealed normal exon 23 and exon 24 transcripts. Allele
expression analysis was not feasible, because the patient
was homozygous at multiple BRCA1 polymorphisms.
Five deleterious BRCA2 mutations, all localized in exon 11
and including three nonsense and two frameshift muta-
tions, were identified in six patients (Table 2). BRCA2
4109TtoA, BRCA2 4339CtoT and BRCA2 5117CtoG
are novel, whereas BRCA2 5950delTC and BRCA2
6696delTC were previously reported [23,24]. One muta-
tion (BRCA2 6696delTC) recurred in two unrelated
probands. The haplotype of the mutation-bearing chromo-
somes could not be reconstructed, because DNA samples
from relatives of the two patients were not available.
BRCA1 and BRCA2, respectively, accounted for four out
of 68 (6%) and one out of 68 (1%) patients diagnosed
before age 50 years, and for one out of 68 (1%) and five
out of 68 (7%) cases diagnosed after age 50 years.
BRCA1 mutations were found in five out of 117 females
(4%) and in none of 19 males (0%), and BRCA2 muta-
tions were found in four out of 117 females (3%) and in
two out of 19 males (10%). BRCA1 and BRCA2 muta-
tions accounted for the same number of cases among
patients with family history of breast/ovarian cancer (four
out of 66; ie 4% each), whereas BRCA1 and BRCA2
mutations, respectively, accounted for one out of 66 (1%)
and for two out of 64 (3%) of the cases without a family
history (Table 3).
In site-specific female breast cancers, the proportions of
BRCA1 and BRCA2 mutations coincided (four out of 102,
ie 4% each). BRCA1 and BRCA2 equally contributed to
female breast cancers with no familial clustering diagnosed
before age 40 years (one out 28; 4% each) and to female
breast cancers, all ages, with familial clustering in one or
two relatives (three out of 55; 5% each). In the latter subset
of cases, BRCA1 mostly accounted for tumours diagnosed
before age 40 years (two out of eight; 25%) and BRCA2
for tumours diagnosed after age 50 years (three out of 34;
9%). Regardless of family history, the respective contribu-
tions of BRCA1 and BRCA2 to site-specific female breast
cancers diagnosed before age 40 years were 8% (three out
of 36) and 3% (one out of 36). One BRCA1 mutation was
detected among the 15 female probands from breast–
ovarian/ovarian cancer families (7%). This patient was
among the 10 who had a family history of breast/ovarian
cancer (one out of 10, 10%; Table 4).
Among male breast cancers, BRCA2 mutations were
identified in one out of five (20%) patients with a family
history and in one out of 14 (7%) apparently sporadic
cases. No BRCA1 or BRCA2 mutations were found in
female probands with nonfamilial bilateral breast cancer
(10 cases) and with breast cancer associated with gas-
trointestinal, pancreatic or uterine cancers, synchro-
nous/metachronous or in first-degree relative(s) (nine
cases). These cases were all diagnosed after age 40
years (Table 5).
Discussion
We screened the coding sequences of the BRCA1 and
BRCA2 genes in 136 breast/ovarian cancer patients,
including 102 females with breast cancer who were
mostly at moderate risk for mutation-carrier status, 15
females with breast–ovarian/ovarian cancer and 19 males
with breast cancer. The sensitivity of the combined
PTT/SSCP screening assays is reportedly high [16]. The
present results should be regarded as an approximation,
because the following types of mutation are predicted to
escape detection: mutations in noncoding regions, which
are estimated to account for a minimum of 10% of patho-
genetic  BRCA1 and  BRCA2 mutations [5]; missense
mutations in functionally important regions within BRCA1
and BRCA2 exons 11; large deletions undetectable by
PCR-based assays; and mutations within the first and last
180 nucleotides of the amplicons analyzed by PTT. In
spite of these limitations, the present study contributes
evidence that is useful for assessing the importance of
BRCA1 and BRCA2 mutations in patients who are not in
high-risk families from outbred populations.
In contrast to studies on North and East European popula-
tions [10,14,25–27], the present results indicate a lack of
relevant founder effects for BRCA1- and BRCA2-related
disease in the sample of patients analyzed, which is in
agreement with other Italian studies [24,28–30] and with
ethnical and historical data [15]. The BRCA1 mutations
detected in the present study were previously reported in
families with high cancer incidence of different ethnic or
geographic origin, but not in other Italian surveys
[24,28–30]. Interestingly, three of the six BRCA2 muta-
tions were nonsense and three were novel. BRCA2
6696delTC, reported in another series of Italian breast
cancer patients [24] but only twice in the Breast Cancer
Information Core database, was the only mutation
detected more than once. This mutation may represent a
candidate frequent mutation in the Italian population. A
possible common origin of the mutation detected in two
Breast Cancer Research    Vol 2 No 4 Ottini et alunrelated patients could not be verified, however, because
the haplotypes of the mutation-bearing chromosomes
could not be reconstructed.
The contributions of BRCA1 and BRCA2 to breast/
ovarian cancer in Italian patients appear to be less signifi-
cant than in patients from communities with founder muta-
tions [4,10,31,32]. The present results are in agreement
with recent direct estimates on other outbred populations,
which indicate that 7–10% of all female breast cancers
that occur before age 40 years are due to BRCA1/
BRCA2 [4,8,32,33]. Moreover, the 8% BRCA1 mutation
rate found in women with site-specific breast cancer diag-
nosed before age 40 years, regardless of family history, is
consistent with an indirect estimate that 5.3% of all female
breast cancers among those who are under 40 years old
may be due to mutations in BRCA1 [34].
Overall, BRCA1 and BRCA2 equally contributed to site-
specific breast cancer in patients who reported one or two
breast cancer-affected first-/second-degree relative(s) or
who were diagnosed before age 40 years in the absence of
a family history. This is consistent with recent data [4,7] that
indicated that the respective frequencies of BRCA1 and
BRCA2 mutations are comparable in early onset breast
cancer. Considering the total population of patients ana-
lyzed here, however, BRCA1 and BRCA2 mutations were
mostly found in cases with disease diagnosis before and
after age 50 years, respectively. Moreover, in cases with
familial clustering of site-specific breast cancer, BRCA1
mostly accounted for tumours diagnosed before age 40
years, and BRCA2 for tumours diagnosed after age 50
years. This is in agreement with a trend, observed in other
populations, for the proportion of cases with BRCA2 muta-
tions to increase, and the proportion with mutations in
BRCA1 to decrease as the age at cancer onset increases
[4,31,35,36]. As in other studies [4], the frequency of
BRCA1/BRCA2 mutations taken together was lower than
the estimated frequencies at comparable ages for all sus-
ceptibility alleles derived from the CASH study [3]. The dis-
crepancy between direct data derived from
BRCA1IBRCA2 mutational analysis and CASH estimates
could be due to several factors, including contribution(s) of
gene(s) other than BRCA1/BRCA2, differences between
populations and relative insensitivity of mutational screening.
In the present study, BRCA1 mutations were detected in
only one out of 10 cases from breast/ovarian and site-spe-
cific ovarian cancer families. This is a low proportion com-
pared with studies that suggested that BRCA1 and
BRCA2 are responsible for the large majority of
breast/ovarian cancer families, with the greater proportion
due to BRCA1 [2–5,7,19,31]. In this respect, the limits of
mutation detection techniques and the small number of
breast/ovarian and site-specific ovarian cancer cases
tested should be taken into account, together with the fact
that most of the probands examined here were from fami-
lies with only one case of ovarian cancer.
As expected, BRCA2 mutations were detected in male
breast cancer patients. BRCA2 mutations were found in
20% of the males reporting familial clustering of breast
cancer. In the males with no family history of
breast/ovarian cancer, the proportion of carriers of
BRCA2 mutations (7%) was comparable to that obtained
for BRCA1 and BRCA2 combined in site-specific female
breast cancer patients (8%). The overall proportion of
cancer-affected males with BRCA2 mutations (10%) was
high compared with data from other outbred populations,
but was lower than that reported for populations with
founder effects [4,11–14,37].
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